Current Funding Opportunities

To visit the NCI grant site, click here


Use your device's search function to find a specific disease or funding source. 


Breast 


Avon Breast Cancer Crusade 2017 Funding 
These research initiative funds translational research using clinical studies, human cell culture, epidemiologic, and other progressive approaches to understand the causes of breast cancer and develop new treatments.

Access to Care - Support Services Program

Supports programs providing services and education to women and men diagnosed with breast cancer, including nutrition support, counseling and referral programs, financial assistance programs, and information services. Application is by invitation only. To seek an invitation, please send a description of the proposed program to grants@avonbcc.org.



Colorectal

Accelerating Colorectal Cancer Screening and Follow Up Through Implementation Science (ACCSIS): Coordinating Center (U24)
This Funding Opportunity Announcement (FOA) is associated with the Beau Biden Cancer Moonshot Initiative that is intended to accelerate cancer research. The purpose of this FOA is to promote research in colorectal cancer screening, follow-up, and referral-to-care among target populations for whom screening rates are below national standards. Specifically, this FOA targets the following area designated as a scientific priority by the Blue Ribbon Panel (BRP): Prevention and Screening: Implementation of Evidence-based Approaches. 

Letter of Intent and Application Deadlines:
December 18, 2017; January 18, 2018

Learn More>>



Accelerating Colorectal Cancer Screening and Follow Up Through Implementation Science (ACCSIS) (UG3/UH3)
This Funding Opportunity Announcement (FOA) is associated with the Beau Biden Cancer Moonshot Initiative that is intended to accelerate cancer research. The purpose of this FOA is to promote research in colorectal cancer screening, follow-up, and referral-to-care among target populations for whom screening rates are below national standards. Specifically, this FOA targets the following area designated as a scientific priority by the Blue Ribbon Panel (BRP): Prevention and Screening: Implementation of Evidence-based Approaches. 

Letter of Intent and Application Deadlines: December 18, 2017; January 18, 2018





Utilizing the PLCO Biospecimens Resource to Bridge Gaps in Cancer Etiology and Early Detection Research (U01) 
This Funding Opportunity Announcement (FOA) encourages the submission of applications that propose to advance research in cancer etiology and early detection biomarkers, utilizing the advantages of the unique biorepository resources of the NCI-sponsored Prostate, Lung, Colorectal, and Ovarian Cancer (PLCO) Screening Trial. The PLCO Biorepository offers high-quality, prospectively collected, serial pre-diagnostic blood samples from the PLCO screened arm participants, and a onetime collection of buccal cells from the control arm participants. Available data associated with the biospecimens includes demographic, diet, lifestyle, smoking, screening results, and clinical data. This FOA supports a wide range of cancer research including, but not limited to, biochemical and genetic analyses of cancer risk, as well as discovery and validation of early detection biomarkers. The proposed research project must involve use of PLCO biospecimens; additionally, it should also take advantage of the unique characteristics of the PLCO biospecimens. Research projects that do not involve the use of PLCO biospecimens will not be supported under this FOA.  
 
Application Due Date: Application Receipt/Submission Date(s): February 15, 2018; August 15, 2018, by 5:00 PM local time of applicant organization.
 

Lung 


Utilizing the PLCO Biospecimens Resource to Bridge Gaps in Cancer Etiology and Early Detection Research (U01) 
This Funding Opportunity Announcement (FOA) encourages the submission of applications that propose to advance research in cancer etiology and early detection biomarkers, utilizing the advantages of the unique biorepository resources of the NCI-sponsored Prostate, Lung, Colorectal, and Ovarian Cancer (PLCO) Screening Trial. The PLCO Biorepository offers high-quality, prospectively collected, serial pre-diagnostic blood samples from the PLCO screened arm participants, and a onetime collection of buccal cells from the control arm participants. Available data associated with the biospecimens includes demographic, diet, lifestyle, smoking, screening results, and clinical data. This FOA supports a wide range of cancer research including, but not limited to, biochemical and genetic analyses of cancer risk, as well as discovery and validation of early detection biomarkers. The proposed research project must involve use of PLCO biospecimens; additionally, it should also take advantage of the unique characteristics of the PLCO biospecimens. Research projects that do not involve the use of PLCO biospecimens will not be supported under this FOA.  
 
Application Due Date: Application Receipt/Submission Date(s): February 15, 2018; August 15, 2018, by 5:00 PM local time of applicant organization.

Melanoma

Melanoma Research Alliance 
The Melanoma Research Alliance (MRA) is pleased to announce a Request for Proposals (RFP) for high-impact pre-clinical, translational, and early clinical research that has the potential to lead to near-term clinical application in melanoma prevention, detection, diagnosis, staging, and treatment. This cycle, proposals will be accepted for Team Science Awards, Young Investigator Awards, and Academic-Industry Partnership Awards for Established Investigators.

Application Deadline: 
November 17, 2017: Young Investigator Award and Academic-Industry Partnership Award proposals 

Ovarian

Department of Defense Ovarian Cancer Research Program Funding Opportunities

FY17 OCRP Program Announcements and General Application Instructions for the following award mechanisms are anticipated to be posted on Grants.gov in February 2017.  Pre-application and application deadlines will be available when the Program Announcements are released. 

Clinical Development Award
Must be an independent investigator at or above the level of Assistant Professor (or equivalent)

Investigator-Initiated Research Award
Must be an independent investigator at or above the level of Assistant Professor (or equivalent)

Ovarian Cancer Academy Award – Early-Career Investigator
Must be within 3 years of his/her last postdoctoral research position (Ph.D) or clinical fellowship (M.D.), or equivalent as of the full application submission deadline.  A letter attesting to eligibility is required.

Pilot Award
Established Investigator:  Independent investigator for whom it has been more than 3 years since his/her last postdoctoral research position (Ph.D) or clinical fellowship (M.D.), or equivalent; or
Early-Career Investigator:  Investigators must meet one of the following criteria by the application submission date: Must be within 3 years of his/her last postdoctoral research position (Ph.D) or clinical fellowship (M.D.) OR In a postdoctoral research position (Ph.D), or clinical fellowship (M.D.), or equivalent.  

Applications must be submitted through the federal government’s single-entry portal, Grants.gov.  Submission deadlines are not available until the Program Announcements are released.  


Utilizing the PLCO Biospecimens Resource to Bridge Gaps in Cancer Etiology and Early Detection Research (U01) 
This Funding Opportunity Announcement (FOA) encourages the submission of applications that propose to advance research in cancer etiology and early detection biomarkers, utilizing the advantages of the unique biorepository resources of the NCI-sponsored Prostate, Lung, Colorectal, and Ovarian Cancer (PLCO) Screening Trial. The PLCO Biorepository offers high-quality, prospectively collected, serial pre-diagnostic blood samples from the PLCO screened arm participants, and a onetime collection of buccal cells from the control arm participants. Available data associated with the biospecimens includes demographic, diet, lifestyle, smoking, screening results, and clinical data. This FOA supports a wide range of cancer research including, but not limited to, biochemical and genetic analyses of cancer risk, as well as discovery and validation of early detection biomarkers. The proposed research project must involve use of PLCO biospecimens; additionally, it should also take advantage of the unique characteristics of the PLCO biospecimens. Research projects that do not involve the use of PLCO biospecimens will not be supported under this FOA.  
 
Application Due Date: Application Receipt/Submission Date(s): February 15, 2018; August 15, 2018, by 5:00 PM local time of applicant organization.
 

Pancreatic

2018 Catalyst Grant 
Supports a junior faculty to conduct pancreatic cancer research and establish successful career paths in the field with a $500,000 grant over three years. Proposed research may be basic, translational, clinical, or epidemiological in nature and must have direct applicability and relevance to pancreatic cancer. 

Application Deadline:
 December 15, 2017

Learn More>> 



2018 Translational Research Grant 
Supports independent investigators conducting high priority pancreatic cancer research that is poised for important translational next steps with a $500,000 grant over two years. Proposed research should aim to identify novel targets and approaches to the treatment of pancreatic cancer or understand and circumvent treatment resistance. 

Application Deadline: January 15, 2018 

Learn More>> 


The Pancreatic Cancer Detection Consortium (U01)
This Funding Opportunity Announcement (FOA) invites applications from multi-disciplinary teams of researchers and clinicians to establish the Pancreatic Cancer Detection Consortium (PCDC) to conduct research to improve the detection of early stage pancreatic ductal adenocarcinoma (PDAC) and characterization of its precursor lesions.

Application Due Date: April 6, 2018

Learn More>>

AVON 

Avon Breast Cancer Crusade 2017 Funding 

These research initiative funds translational research using clinical studies, human cell culture, epidemiologic, and other progressive approaches to understand the causes of breast cancer and develop new treatments.


Access to Care - Support Services Program

Supports programs providing services and education to women and men diagnosed with breast cancer, including nutrition support, counseling and referral programs, financial assistance programs, and information services. Application is by invitation only. To seek an invitation, please send a description of the proposed program to grants@avonbcc.org.


Cancer Moonshot


Accelerating Colorectal Cancer Screening and Follow Up Through Implementation Science (ACCSIS): Coordinating Center (U24) 
This Funding Opportunity Announcement (FOA) is associated with the Beau Biden Cancer Moonshot Initiative that is intended to accelerate cancer research. The purpose of this FOA is to promote research in colorectal cancer screening, follow-up, and referral-to-care among target populations for whom screening rates are below national standards. Specifically, this FOA targets the following area designated as a scientific priority by the Blue Ribbon Panel (BRP): Prevention and Screening: Implementation of Evidence-based Approaches.  

Letter of Intent and Application Deadlines:
 December 18, 2017; January 18, 2018 

Learn More>>



Accelerating Colorectal Cancer Screening and Follow Up Through Implementation Science (ACCSIS) (UG3/UH3) 
This Funding Opportunity Announcement (FOA) is associated with the Beau Biden Cancer Moonshot Initiative that is intended to accelerate cancer research. The purpose of this FOA is to promote research in colorectal cancer screening, follow-up, and referral-to-care among target populations for whom screening rates are below national standards. Specifically, this FOA targets the following area designated as a scientific priority by the Blue Ribbon Panel (BRP): Prevention and Screening: Implementation of Evidence-based Approaches.  

Letter of Intent and Application Deadlines: December 18, 2017; January 18, 2018




Human Tumor Atlas Network: Data Coordinating Center (U24)
This Funding Opportunity Announcement (FOA) is associated with the Beau Biden Cancer Moonshot Initiative that is intended to accelerate cancer research. The purpose of this FOA is to promote research that results in a comprehensive view of the dynamic multidimensional tumor ecosystem. Specifically, this FOA targets the following area(s) designated as a scientific priority by the Blue Ribbon Panel (BRP): Generation of Human Tumor Atlases. Through this FOA, the National Cancer Institute (NCI) invites cooperative agreement applications to develop a Human Tumor Atlas Network (HTAN) Data Coordinating Center (DCC). The HTAN-DCC will have two major areas of responsibility: (1) Data Standards, Storage, Analysis, and Dissemination; and, (2) Consortium Coordination and Outreach.

Letter of Intent and Application Deadlines: December 18, 2017; January 18, 2018




Pre-Cancer Atlas (PCA) Research Centers (U2C)
This Funding Opportunity Announcement (FOA) is associated with the Beau Biden Cancer Moonshot Initiative that is intended to accelerate cancer research. The purpose of this FOA is to promote research that results in a comprehensive view of the dynamic multidimensional tumor ecosystem. Specifically, this FOA targets the following area(s) designated as a scientific priority by the Blue Ribbon Panel (BRP): Generation of Human Tumor Atlases. 

For the purposes of this FOA, a human pre-cancer atlas is defined as a multidimensional cellular, morphological and molecular mapping of human pre-malignant tumors, complemented with critical spatial information (at cellular and/or molecular level) that facilitate visualization of the structure, composition, and multiscale interactions within the tumor ecosystem over time resulting in progression or regression of the tumors. Through this FOA, the National Cancer Institute (NCI) invites applications for the PCA Research Centers, a collaborative research initiative that aims to construct comprehensive, dynamic, high-resolution, multidimensional, multiparametric, temporal and scalable atlases of pre-cancerous lesions and their surrounding microenvironment for select organ sites, including high-priority cancers that disproportionally affect minority and underserved patients. A deeper understanding of the transition from pre-malignant to malignant state as a function of time will allow the development of more precise risk stratification methods and effective early intervention strategies. Each PCA Research Center will lead the construction of at least one human pre-cancer atlas for use by the research and clinical communities. The data and analytical tools generated by the PCA Research Centers will be made available to the research community through the aid of the HTA Data Coordinating Center.


Letter of Intent and Application Deadlines: December 18, 2017; January 18, 2018 




Human Tumor Atlas Research Centers (U2C)
This Funding Opportunity Announcement (FOA) is associated with the Beau Biden Cancer Moonshot Initiative that is intended to accelerate cancer research. The purpose of this FOA is to promote research that results in a comprehensive view of the dynamic multidimensional tumor ecosystem. Specifically, this FOA targets the following area designated as a scientific priority by the Blue Ribbon Panel (BRP): Generation of Human Tumor Atlases.

Through this FOA, the National Cancer Institute (NCI) invites cooperative agreement (U2C) applications for HTA Research Centers, a collaborative research initiative that aims to build tumor atlases through the dynamic multiparameter characterizations of cancerous lesions across high-priority cancer types, including those that disproportionally effect minority and underserved patients. The Human Tumor Atlas (HTA) Research Centers will each lead construction of at least one, but no more than three, organ-specific human tumor atlases that describe overall cellular and molecular architecture of critical transitions in tumorigenesis for use by the research and clinical communities. The data and analytical tools generated by the HTA Research Centers will be made available to the research community through the activities of the HTAN Data Coordinating Center (U24).

Letter of Intent and Application Deadlines: December 18, 2017; January 18, 2018 


Learn More>>


Analyzing and Interpreting Clinician and Patient Adverse Event Data to Better Understand Tolerability (U01) 
This Funding Opportunity Announcement (FOA) is associated with the Beau Biden Cancer Moonshot Initiative that is intended to accelerate cancer research. The purpose of this FOA is to promote research on developing the descriptive, inferential, and graphical statistical methods for data generated in clinical trials including Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE™) items. Specifically, this FOA targets the following area designated as a scientific priority by the Blue Ribbon Panel (BRP): Accelerate research that can identify approaches to monitor and manage patient-reported symptoms.

Letter of Intent and Application Deadlines: December 17, 2017; January 17, 2018  

Learn More>>


Coordinating Center for Research Centers for Improving Management of Symptoms During and Following Cancer Treatment (U24) 
This Funding Opportunity Announcement (FOA) is associated with the Beau Biden Cancer Moonshot Initiative established to accelerate cancer research. Specifically, this FOA targets the following area designated as a scientific priority by the Blue Ribbon Panel (BRP): the Implementation of Integrated and Evidenced-based Symptom Management Throughout the Cancer Trajectory. The purpose of this specific FOA is to promote research on the implementation and evaluation of comprehensive symptom management systems for use in cancer care delivery through a Research Consortium. This research will provide new insights and valuable evidence that can be used to guide efforts on a nation-wide basis to improve symptom control for cancer patients during treatment and survivorship.

Letter of Intent and Application Deadlines:
 December 17, 2017; January 17, 2018 

Learn More>>


Research Centers for Improving Management of Symptoms During and Following Cancer Treatment (UM1) 
This Funding Opportunity Announcement (FOA) is associated with the Beau Biden Cancer Moonshot Initiative established to accelerate cancer research. Specifically, this FOA targets the following area designated as a scientific priority by the Blue Ribbon Panel (BRP): the Implementation of Integrated and Evidenced-based Symptom Management Throughout the Cancer Trajectory. The purpose of this specific FOA is to promote research on the implementation and evaluation of integrated symptom monitoring and management systems for use in cancer care delivery through a Research Consortium. This research will provide new insights and valuable evidence that can be used to guide efforts on a nation-wide basis to improve symptom control for cancer patients during treatment and survivorship.

Letter of Intent and Application Deadlines:
 December 17, 2017; January 17, 2018  

Learn More>>


Immuno-Oncology Translation Network (IOTN): Cellular Immunotherapy Data Resource (CIDR) (U24)
This Funding Opportunity Announcement (FOA) is associated with the Beau Biden Cancer Moonshot Initiative that is intended to accelerate cancer research. Specifically, this FOA targets the following area designated as scientific priority by the Blue Ribbon Panel (BRP): Recommendation B. Create a translational science network devoted exclusively to immunotherapy approaches to treat and prevent adult cancers. The goal of the network is to foster collaborative team science approaches to accelerate the discover of new immune targets and evaluate novel immune-based therapies and combination approaches that eliminate established cancers in adults or to prevent cancers before they occur. The purpose of this specific FOA is to establish a Data Resource associated with clinical trials in cellular immunotherapy as a component of the Immuno-Oncology Translation Network (IOTN).

Letter of Intent and Application Deadlines: December 16, 2017; January 16, 2018  

Learn More>>


Immuno-Oncology Translation Network (IOTN): Data Management and Resource-Sharing Center (DMRC) (U24)
This Funding Opportunity Announcement (FOA) is associated with the Beau Biden Cancer Moonshot Initiative that is intended to accelerate cancer research. Specifically, this FOA targets the following area designated as scientific priority by the Blue Ribbon Panel (BRP): Recommendation B. Create a translational science network devoted exclusively to immunotherapy approaches to treat and prevent adult cancers. The goal of the network is to foster collaborative team science approaches to accelerate the discover of new immune targets and evaluate novel immune-based therapies and combination approaches that eliminate established cancers in adults or to prevent cancers before they occur. The purpose of this FOA is to establish a Data Management and Resource-sharing Center to provide overall support for the Immuno-Oncology Translational Network (IOTN) and to integrate the research activities of the IOTN with other Cancer Moonshot Initiative programs.

Letter of Intent and Application Deadlines: December 16, 2017; January 16, 2018

Learn More>>


Immuno-Oncology Translation Network (IOTN): Cancer Immunoprevention Research Projects (U01)
This Funding Opportunity Announcement (FOA) is associated with the Beau Biden Cancer Moonshot Initiative that is intended to accelerate cancer research. Specifically, this FOA targets the following area designated as scientific priority by the Blue Ribbon Panel (BRP): Recommendation B. Create a translational science network devoted exclusively to immunotherapy approaches to treat and prevent adult cancers. The goal of the network is to foster collaborative team science approaches to accelerate the discover of new immune targets and evaluate novel immune-based therapies and combination approaches that eliminate established cancers in adults or to prevent cancers before they occur. The purpose of this specific FOA is to establish Cancer Immunoprevention Research Projects that will function as components of a Cancer Immunotherapy Consortium (CIC), which will also include Cancer Immunotherapy Research Projects.


Letter of Intent and Application Deadlines: December 16, 2017; January 16, 2018 

Learn More>>


Immuno-Oncology Translation Network (IOTN): Cancer Immunotherapy Research Projects (U01)
This Funding Opportunity Announcement (FOA) is associated with the Beau Biden Cancer Moonshot Initiative that is intended to accelerate cancer research. Specifically, this FOA targets the following area designated as scientific priority by the Blue Ribbon Panel (BRP): Recommendation B. Create a translational science network devoted exclusively to immunotherapy approaches to treat and prevent adult cancers. The goal of the network is to foster collaborative team science approaches to accelerate the discover of new immune targets and evaluate novel immune-based therapies and combination approaches that eliminate established cancers in adults or to prevent cancers before they occur. The purpose of this FOA is to establish a Cancer Immunotherapy Consortium (CIC) composed of organ site-specific Cancer Immunotherapy Research Projects as a component of the Immuno-Oncology Translation Network (IOTN).

Letter of Intent and Application Deadlines: December 16, 2017; January 16, 2018

Learn More>>

Approaches to Identify and Care for Individuals with Inherited Cancer Syndromes (U01)
This Funding Opportunity Announcement (FOA) is associated with the Beau Biden Cancer Moonshot Initiative that is intended to accelerate cancer research. The purpose of this FOA is to increase case ascertainment and optimize delivery of evidence-based healthcare for individuals at high risk of cancer due to an inherited genetic susceptibility. Specifically, this FOA targets the following area designated as a scientific priority by the Blue Ribbon Panel (BRP) Recommendation E: "To realize the potential of cancer prevention and early detection in our nation, NCI should sponsor an initiative to improve the current state of early detection, genetic testing, genetic counseling, and knowledge landscape of the mechanisms and biomarkers associated with cancer development. This initiative should include demonstration projects that will show how cancer screening programs can simultaneously save lives, improve quality of life, and reduce healthcare costs." This Funding Opportunity Announcement (FOA) invites U01 application for projects aimed at identifying best practices to improve case ascertainment of hereditary cancers, with the goal of improving prevention and detection.

Letter of Intent and Application Deadlines: December 9, 2017; January 9, 2018

Learn More>>



Mechanisms of Cancer Drug Resistance and Sensitivity: Coordinating Center (U24)
This Funding Opportunity Announcement (FOA) is associated with the Beau Biden Cancer Moonshot Initiative that is intended to accelerate cancer research. The purpose of this Funding Opportunity Announcement (FOA) is to create a U24 Coordinating Center that will integrate and facilitate trans-disciplinary research across the Drug Resistance and Sensitivity Centers (DRSCs), established under an earlier released RFA-CA-17-009 for U54 specialized centers.

Letter of Intent and Application Deadlines: December 5, 2017; January 5, 2018

Learn More>>


Pediatric Immunotherapy Discovery and Development Network (PI-DDN)(U01)
This Funding Opportunity Announcement (FOA) is associated with the Beau Biden Cancer Moonshot Initiative that is intended to accelerate cancer research. The overall goal of this FOA and the companion FOA, RFA-CA-17-050, is to establish a network of collaborating investigators to identify and advance research opportunities for translating immunotherapy concepts for children and adolescents with cancer toward clinical applications. Specifically, this FOA targets the following area(s) designated as a scientific priority(ies) by the Blue Ribbon Panel (BRP): Recommendation (B) that calls for the establishment of a pediatric immunotherapy translation science network. The network was envisioned by the BRP as focusing on identifying new targets for immunotherapies, developing new pediatric immunotherapy treatment approaches (e.g., cancer vaccines, cellular therapy, combinations of immunotherapy agents, and others), and defining the biological mechanisms by which pediatric tumors evade the immune system. This FOA solicits U01 applications for discrete research projects that address relevant research opportunities (e.g., mechanisms of immune evasion, model development, validation of a single target, etc.), while the companion FOA, RFA-CA-17-050, solicits multi-component U54 Center applications. Successful applicants from both FOAs will become members of the Pediatric Immunotherapy Discovery and Development Network (PI-DDN), which will address and implement the BRP recommendations.

Letter of Intent and Application Deadlines: November 19, 2017; December 19, 2017

Learn More>>


Pediatric Immunotherapy Discovery and Development Network (PI-DDN)(U54)
This Funding Opportunity Announcement (FOA) is associated with the Beau Biden Cancer Moonshot Initiative that is intended to accelerate cancer research. The purpose of this FOA is to establish Centers of collaborating investigators with the goal of identifying and advancing research opportunities for translating immunotherapy concepts for children and adolescents with cancer toward clinical applications. Specifically, this FOA targets the following area designated as a scientific priority by the Blue Ribbon Panel (BRP): Recommendation (B) that calls for the establishment of a pediatric immunotherapy translational science network. The network was envisioned by the BRP as focusing on identifying new targets for immunotherapies, developing new pediatric immunotherapy treatment approaches (e.g., cancer vaccines, cellular therapy, combinations of immunotherapy agents, and others), and defining the biological mechanisms by which pediatric tumors evade the immune system. The Pediatric Immunotherapy Discovery and Development Network (PI-DDN) Centers will address and implement these BRP recommendations.

Letter of Intent and Application Deadlines: November 19, 2017; December 19, 2017 

Learn More>>



The Howard Hughes Medical Institute

The Hanna H. Gray Fellows Program Competition

The goal of the Hanna H. Gray Fellows Program is to recruit and retain individuals who are from gender, racial, ethnic, and other groups underrepresented in the life sciences, including those from disadvantaged backgrounds, early in their careers. The Hanna H. Gray Fellows Program supports early-career life scientists in academic labs across the U.S. The 2018 competition is now open.

Application Deadline: January 10, 2018

NCCN

NCCN Young Investigator Award
The NCCN Foundation invites proposals from young investigators with innovative ideas and an interest in improving the quality, effectiveness, and efficiency of care provided to cancer patients. Research projects may pertain to: 1) The application of the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®); or 2) Address new prevention, detection or treatment approaches for cancer and its translation into clinical care.

The award is open to physicians, scientists, nurses and others working in an oncology laboratory, clinical research or clinical setting, or cancer control program in one of NCCN's 27 Member Institutions, who: 1) Have a first full-time appointment as an Assistant Professor, Instructor, or an equivalent level, and 2) Are MD's, PhD's or, for nurses and others, have an advanced degree.

Each NCCN Member Institution can nominate up to two applicants who may submit research applications relating to one or both of the categories of investigation summarized below: 1) Research pertaining to the NCCN Guidelines® 2) New prevention, detection or treatment approaches for cancer and their translation into clinical care.

Nomination and Application Deadlines: For nomination consideration, please send a short research summary proposal and your CV to Robert Garofalo and Christina Bates by 5:00 PM on Wednesday, November 15, 2017. Two nominations for the NCCN Young Investigator Award will be sent from Yale Cancer Center/Smilow Cancer Hospital. Full applications will need to be submitted to NCCN by January 27, 2018.

NIH/NCI

Clinical and Epidemiological Research on Chronic Disease in the Caribbean
NCI Center for Global Health (CGH) helps reduce the global burden of cancer by strengthening research capacity through funding and training. The purpose of this Funding Opportunity Announcement (FOA) is to support US-Caribbean collaborative research to develop or extend cohort or surveillance studies on chronic disease in the Caribbean region that are aligned with existing publicly available US datasets. 

Application Deadlines: November 15, 2017, November 15, 2018, November 15, 2019


Clinical and Translational Exploratory/Developmental Studies (R21)  
This Funding Opportunity Announcement (FOA) supports the development of new exploratory research in cancer diagnosis, treatment, imaging, symptom/toxicity, and prevention clinical trials; correlative studies associated with clinical trials; novel cancer therapeutic, symptom/toxicity, and preventive agent development, radiotherapy development activities, and mechanism-driven combinations; and innovative preclinical studies--including the use of new clinically-relevant models and imaging technologies--which could lead to first-in-human clinical trials. 

Application Receipt/Submission Date(s): November 22, 2017; March 22, 2018; July 19, 2018; November 22, 2018; March 22, 2018, by 5:00 PM local time of applicant organization. 

Learn More>> 



Pilot and Feasibility Studies Evaluating the Role of RNA Modifications (the 'epitranscriptome') in Cancer Biology (R21) 
This Funding Opportunity Announcement (FOA) encourages basic research into the role of RNA chemical modifications and their corresponding writers, readers and erasers in the initiation and progression of cancer. 

Application Receipt/Submission Date(s): November 22, 2017; March 22, 2018; July 19, 2018; November 22, 2018; March 22, 2018, by 5:00 PM local time of applicant organization. 

Learn More>> 



Exploratory Grants in Cancer Epidemiology and Genomics Research (R21)   
This funding opportunity announcement (FOA) invites applications for research on cancer epidemiology, genomics, and risk assessment. The overarching goal is to provide support to promote the early and conceptual stages of research efforts on novel scientific ideas that have the potential to substantially advance cancer research. 

Application Receipt/Submission Date(s): November 22, 2017; March 22, 2018; July 19, 2018; November 22, 2018; March 22, 2018, by 5:00 PM local time of applicant organization. 

Learn More>> 



Emerging Questions in Cancer Systems Biology (U01)   
This Funding Opportunity Announcement (FOA) invites cooperative agreement applications for Research Projects that utilize systems biology approaches to address emerging questions in cancer initiation, progression, and treatment.

Application Receipt/Submission Date(s): November 24, 2017; June 22, 2018; November 23, 2018, by 5:00 PM local time of applicant organization.

Learn More>> 



 Cancer Clinical Investigator Team Leadership Award for Fiscal Year (FY) 2018
This is a reissue of the FY 2017 administrative supplement award announcement. The Cancer Clinical Investigator Team Leadership Award (CCITLA) is an administrative supplement award which recognizes and supports outstanding clinical investigators with records of developing and promoting a culture of successful clinical research. It is the FY 2018 Cancer Clinical Investigator Team Leadership Award (CCITLA) 2 intent of the CCITLA to support mid-level clinical investigators at NCI-designated Cancer Centers who are participating extensively in NCI-funded clinical trials and clinical research efforts. The award is also intended to retain clinical investigators in academic clinical research careers. A candidate for the CCITLA must be nominated by the Cancer Center Director.

Application Deadline:
November 27, 2017

Learn More>>



Cancer Tissue Engineering Collaborative: Enabling Biomimetic Tissue-Engineered Technologies for Cancer Research (U01) 
This Funding Opportunity Announcement (FOA) will support the development and characterization of state-of-the-art biomimetic tissue-engineered technologies for cancer research. 

Application Receipt/Submission Date(s): November 30, 2017; May 30, 2018; November 30, 2018, by 5:00 PM local time of applicant organization. 

Learn More>>



Cooperative Agreement to Develop Targeted Agents for Use with Systemic Agents Plus Radiotherapy (U01)
The purpose of this Funding Opportunity Announcement (FOA) is to invite cooperative agreement (U01) applications that propose studies to enhance pre-clinical in vitro and in vivo testing of NCI-prioritized molecularly targeted anti-cancer agents for use with radiation therapy combined with systemic chemotherapy. 

Application Due Date: December 14, 2017 

Learn More>> 



Academic-Industrial Partnerships for Translation of Technologies for Cancer Diagnosis and Treatment (R01)
This Funding Opportunity Announcement (FOA) encourages applications from research partnerships formed by academic and industrial investigators, to accelerate the translation of technologies, methods, assays or devices, and/or systems for preclinical or clinical molecular diagnosis or in vitro imaging that are designed to solve a targeted cancer problem.

Application Due Date: January 8, 2018

Learn More>>


Minority Patient-Derived Xenograft (PDX) Development and Trial Centers (M-PDTCs) (U54)   

The main goals for this initiative include: a) Development of racially/ethnically diverse PDX models; b) Development of methods for preclinical testing of single agents and drug combinations; and c) Conducting response studies of PDX models, primarily from racially/ethnically diverse populations, to develop novel therapeutic strategies.


Application Due Date: January 18, 2018

Learn More>>



Feasibility and Planning Studies for Development of Specialized Programs of Research Excellence (SPOREs) to Investigate Cancer Health Disparities (P20)  

The goals for this FOA include the development of translational research programs focused upon investigating cancer health disparities. The P20 grants will support feasibility and planning activities to build cancer health disparities research programs, with the expectation that the research programs will become competitive for a full Specialized Programs of Research Excellence (SPORE).

Application Due Date: January 18, 2018  




Feasibility Studies to Build Collaborative Partnerships in Cancer Research (P20) 
Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) invites P20 planning grant applications for  developing collaborative partnership between institutions serving underserved health disparity populations and underrepresented students (ISUPS) and NCI- designated Cancer Centers. 

Application Due Date: January 29, 2018 

Learn More>>

Pancreatic Cancer Action Network

2018 Catalyst Grant
Supports a junior faculty to conduct pancreatic cancer research and establish successful career paths in the field with a $500,000 grant over three years. Proposed research may be basic, translational, clinical, or epidemiological in nature and must have direct applicability and relevance to pancreatic cancer. 

Application Deadline:
December 15, 2017

Learn More>>



2018 Translational Research Grant
Supports independent investigators conducting high priority pancreatic cancer research that is poised for important translational next steps with a $500,000 grant over two years. Proposed research should aim to identify novel targets and approaches to the treatment of pancreatic cancer or understand and circumvent treatment resistance.

Application Deadline: January 15, 2018

Learn More>>


The Pancreatic Cancer Detection Consortium (U01)  
This Funding Opportunity Announcement (FOA) invites applications from multi-disciplinary teams of researchers and clinicians to establish the Pancreatic Cancer Detection Consortium (PCDC) to conduct research to improve the detection of early stage pancreatic ductal adenocarcinoma (PDAC) and characterization of its precursor lesions. 

Application Due Date: April 6, 2018 

Learn More>>


The Yale Cancer Center Internal Grant Program aims to provide funds for innovative, high quality start-up cancer research programs and provide new investigators with experience and guidance in the grant-writing process. 

The criteria for funding is high quality, innovative cancer research with a likelihood to result in NIH-funded cancer research and encourage collaborations within YCC. Grant competitions will be announced in DirectConnect and will undergo an anonymous NIH-style peer review with written reviews provided to applicants. 

Click to see all the Internal Grants from 2012-2016.



Yale and the Liberia Ministry of Health and Liberia College of Physicians and Surgeons Opportunity 
Yale and the Liberia Ministry of Health and Liberia College of Physicians and Surgeons are seeking INTERNAL MEDICINE AND ITS SUBSPECIALTIES (cardiology, gastroenterology, pulmonary, heme/onc, ID) and lab medicine to serve in Liberia. The Liberia Ministry of Health, in conjunction with the World Bank, has established the Health Workforce Program (“HWP”), a seven-year project, which aims to bolster and expand the health education infrastructure and healthcare workforce necessary to create a high quality and sustainable healthcare system in Liberia. Yale School of Medicine has been identified to help develop a sustainable model to train specialists in internal medicine.

Interested applicants are encouraged to submit a copy of their CV to asghar.rastegar@yale.edu along with a one-page cover letter. Currently accepting applications for the 2017-2018 academic year (July 2017-June 2018).

Learn More>>





Yale Center for Clinical Investigation (YCCI)
The Yale Center for Clinical Investigation (YCCI) is pleased to announce the 2017 round of pilot grants. YCCI’s pilot program is a funding venue for conducting small-scale research projects to generate data that potentially could lead to further research and funding opportunities.

YCCI will accept proposals in the following categories:

Clinical junior faculty pilot award: This award is intended to support junior clinician educator faculty who are interested in developing research as a component of their academic life. We anticipate the awardees will be very active clinicians, who would benefit from a period of protected time and resources to pursue research ideas. The primary aim of these awards is to provide early career pilot support and mentorship to allow a career trajectory which successfully integrates clinical care and research. Award amount: Up to 20% salary support (up to the NIH cap) and $20,000 research support per year for up to 2 years.

Lifespan Research: This award is aimed at fostering interdisciplinary teams to work collaboratively on key research that may lead to the next phase of discovery. These projects should be strategically targeted to conduct research that will lead to the next step along the road to translation. Award amount: Up to $50,000 research support per year for up to 2 years.

Community-Engaged Research: The purpose of this funding opportunity is to provide pilot awards to support community engagement projects. Community engagement can take many forms, as NCATS now defines community very broadly, including: patients (local and online communities); nonprofit organizations; faith-based communities; advocacy groups; governmental agencies; community-based clinicians (hospitals, practices, and clinics) and health care delivery systems; industry; and other entities. Award amount: Up to $75,000 research support per year for up to 2 years.

Letters of Intent and Application Deadlines:LOI - November 20, 2017; Application - December 18, 2017

Learn More>>


The St. Baldrick's Foundation
Research Grants ▪ Scholars ▪ Summer Fellows ▪ International Scholars ▪ Supportive Care Research (all faculty)

For faculty and postdocs conducting research to understand the biology of childhood cancers and discover leads to more effective treatments.

Topics of interest also include, but are not limited to: adolescents and young adults; survivorship, outcomes, and quality of life; supportive care; epidemiologic studies; and alternative therapies.

$ vary by award up to a maximum of $110,000 per year.

Internal Deadline:
November 27, 2017

Learn More>>



The Mary Kay Foundation
Innovative Translational Cancer Research 2018 (all faculty)

For junior and senior faculty conducting innovative translational research in ovarian, uterine, breast or cervical cancer. Translational research is broadly defined as research that will provide a scientific link between laboratory research and the clinic. Ultimately, such research would lead to improvement in diagnosis, prognosis, prevention, or treatment of the cancer. Time to be devoted to research: Not restricted.

$100,000 over 2 years. ($100,000)

Internal Application Deadline: November 28, 2017 





Damon Runyon Cancer Research Foundation
Damon Runyon Clinical Investigator Award 2018 (junior faculty)

For junior faculty with the MD or MD/PhD who are conducting patient-oriented cancer research and are capable of moving seamlessly between the laboratory and the patient’s bedside in search of breakthrough treatments. Clinical research supported will include patient-oriented research, epidemiological and behavioral studies, outcomes research and health services research. Initial full-time faculty appointment cannot have been made earlier than July 2014.

$450,000 over 3 years. ($450,000) + up to $100,000 of remaining medical school debt will be retired.

Internal Application Deadline:
November 29, 2017 

Learn More>> 




Lion Heart Fund for Cancer Research
The Lion Hearts are committed to finding a cure for cancer, and breast cancer in particular. In keeping with this mission, they understand the value of funding bright young minds – providing them with pilot funding to kick-start high potential research projects, and/or supporting innovative work requiring bridge funding.

Yale investigators are encouraged to submit proposals of innovative, high-potential projects requiring pilot funding. Projects may be in any area of breast cancer research – basic, translational, clinical, outcomes and population science are all welcomed from any discipline or group of disciplines.

Deadline for proposals: December 4, 2017

Learn More>>



Rudolph J. Anderson Endowed Fellowship

Junior faculty members may be eligible to apply for an endowed Rudolph J. Anderson Fellowship to support a postdoctoral trainee working in the broad area of biochemistry. Application forms for “New” and “Bridge” fellowships are linked below. Each award will fund a postdoctoral associate at a salary of $3,957 per month ($47,484 per year) plus fringe benefits. This meets the current University minimum for a first-year postdoctoral fellow/associate. The goal of the Anderson awards is to support non-tenured faculty members who will benefit from having an additional trainee. Note that it is the faculty member rather than the trainee who must apply. Criteria include the current rank of the faculty member, time at Yale, resources of the lab, and number of lab personnel. A selection committee will review all applications from YSM faculty to determine the awardees. Successful applicants will receive a fellowship slot and will then have up to one year to name the Rudolph J. Anderson Postdoctoral Fellow; it is not necessary for the faculty member to nominate a specific candidate when applying for this fellowship.

Application deadline: December 8, 2017. "New" application form. "Bridge" fellowship application form. Please send to Gerri Emerling at gerri.emerling@yale.edu. Digital applications must be submitted as a single PDF document.



Lion Heart Grants
  • Funding amount based on fundraising annually done by Lion Hearts
  • For Yale Cancer Center members only 
  • To support breast cancer research
  • Committee of Yale Cancer Center members and Lion Heart members review and select grant recipients
  • Administered by Brigid Killelea


SPORE in Lung Cancer Program Awards

Learn More>>

LungSPORE@yale.edu     



V Foundation Pediatric Cancer Grants
  • ONE NOMINEE TO APPLY FOR EITHER THE V SCHOLAR OR TRANSLATIONAL AWARD
  • The nominee must be nominated by their Cancer Center Director if the research institution is a cancer center. If the research institution is not a cancer center, then the department chair or other senior research administrative official who is responsible for the internal nominee 
  • Applicant must be employed at a non-profit research institution 
  • Administered by Gary Kupfer  

American Cancer Society Institutional Research Grants
  • $30,000 for one year
  • For assistant professors only
  • Prior national research grant disqualifies
  • Four awards per year
  • Usually reviewed in December
  • Administered by Joann Sweasy

Rausch Foundation Grants in Community Health
  • $30,000-$50,000 for one year
  • Population science focus
  • Priority to projects with impact to New Haven
  • Administered by Melinda Irwin 

YCC Pilot Grants
  • $50,000 for one year
  • All YCC members eligible to apply
  • Specific project proposed by individual investigator
  • Seven or eight awards per year, distributed among all seven research programs
  • Usually reviewed in Spring
  • Administered by Joann Sweasy
  • For more information, please contact Jan Zulkeski

T-TARE Award
  • Up to $200,000 for one year
  • For teams of investigators
  • Research with a translational focus
  • Major goal is to generate data and evidence of collaboration for multi-investigator grant application
  • Administered by Roy Herbst

Yale Discovery Fund Grants 

  • $450,000 to be spent over three years
  • High-risk/high-reward cancer research
  • Multidisciplinary collaborative research
  • Hope to fund 3 – 4 each year
  • Administered by Dan DiMaio

Leslie Warner Postdoctoral Fellowship
  • ~$42,000 for one year
  • Fellows working in YCC member laboratories eligible to apply
  • Must be in first year of fellowship
  • Four awards every other year
  • Usually reviewed in fall
  • Review organized by Karen Anderson